Dr. Arnab Basu, MD

Medicare patients and services

Medicare patients, 2024

193

Services billed

618

Patients’ average age

73

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 12 companies reported 51 payments worth $68,264 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 7 industry-funded studies in 2025, from 6 companies. The companies reported $846,169 in research payments for these studies, mostly to the institutions running them.

• A phase 3 randomized efficacy and safety study of enzalutamide plus leuprolide enzalutamide monotherapy and placebo plus leuprolide in men with highrisk nonmetastatic prostate cancer progressing after definitive therapy
  Pfizer Inc.
• Immune checkpoint inhibitor combinations with axitinib in 1L locally advanced or metastatic rcc
  Genentech, Inc.
• A Phase III Randomized Open-Label Controlled Multi-Center Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Ch…
  AstraZeneca Pharmaceuticals LP
• Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
  Aveo Pharmaceuticals, Inc. · Completed · NCT04987203
• An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma That Has Progressed After Prior PD-1,L1 and VEGF-Targeted Therapies
  Merck Sharp & Dohme LLC
• A phase 3 randomized efficacy and safety study of enzalutamide plus leuprolide enzalutamide monotherapy and placebo plus leuprolide in men with highrisk nonmetastatic prostate cancer progressing after definitive therapy
  Medivation LLC.
• An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembro…
  Merck Sharp & Dohme LLC

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Jacksonville

• Nayef Abdel-razeq, MD
• Ahmed A. Abdelhakeem, MD
• Yousif Abubakr, MD
• Oluwatayo Adeoye, MD
• Pooja P. Advani, MD
• Sikander Ailawadhi, MD
• Ahmad Al Shihabi, MD
• Mahmood B. Aldapt, MD